Trevi Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Trevi Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.000.000.000.000.000.00
Cost of Revenue0.150.000.000.000.000.00
Gross Profit-0.150.000.000.000.000.00
Operating Expenses
Research & Development39.3823.6819.8322.9822.3319.34
Selling, General & Administrative12.1510.2410.079.4910.167.31
Operating Expenses51.5233.9229.9132.4832.4926.65
Operating Income-51.52-33.92-29.91-32.48-32.49-26.65
Other Income/Expense
Interest Income3.604.751.740.010.180.00
Interest Expense0.00-0.39-1.161.20-0.460.00
Other Income/Expense3.580.470.14-0.290.010.00
Income
Income Before Tax-47.94-29.10-29.19-33.96-32.78-26.07
Income Tax Expense-0.03-0.03-0.04-0.02-0.02-0.02
Net Income-47.91-29.07-29.15-33.94-32.76-26.05
Net Income - Continuous Operations-47.91-29.07-29.15-33.940.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-47.79-33.80-29.86-32.71-32.27-26.03
EBIT-47.94-33.92-29.91-32.76-32.32-26.07
Depreciation & Amortization0.150.120.040.050.05-0.04
Earnings Per Share
Basic EPS----1.00-2.00-
Diluted EPS----1.00-2.00-2.00
Basic Shares Outstanding101.0499.0364.5422.8418.0611.74
Diluted Shares Outstanding101.0499.0364.5422.8418.0611.74